THE CLINICAL PROFILE AND OUTCOME OF TREATMENT OF IMMUNE THROMBOCYTOPENIA PATIENTS IN IMPHAL-Reference-Cited by-同舟云学术

THE CLINICAL PROFILE AND OUTCOME OF TREATMENT OF IMMUNE THROMBOCYTOPENIA PATIENTS IN IMPHAL

Published:2022-03-15 Issue: Volume: Page:135-136
ISSN:
Container-title:PARIPEX INDIAN JOURNAL OF RESEARCH
language:en
Short-container-title:PIJR

Author:

Britina Devi Khumanthem¹,Ginzaniang Tungnung²,Irom Anil Singh³

Affiliation:

1. Post graduate trainee,Department of General medicine,JNIMS,Porompat, Manipur

2. Professor,Department of General Medicine,JNIMS,Porompat,Manipur

3. Associate Professor,Department of General Medicine,JNIMS,Porompat, Manipur

Abstract

Previously termed as idiopathic thrombocytopenic purpura, it is an acquired disorder in which there is immune mediated destruction of platelets and possibly inhibition of release 1 from megakaryocyte. ITP can be classified

Publisher

World Wide Journals

Reference20 articles.

1. Barbara AK.Disorder of platelets and vessel wall.Harrison’s principles of Internal Medicine.20th edition. New York: McGraw Hill 2015;825-26.

2. Rodeghiero F, Stasi R, Gernsheimer T. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.Blood.2009;113:2386–93.

3. Neunert C, Wendy L, Mark C, Alan C, Lawrence SJ, Mark AC, et al. The American Society of Haematology 2019 guidelines for immune thrombocytopenia. Blood. 2019;3 (23): 3829-66.

4. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenic. Blood.2017 May 25;129(21):2829-35..

5. Yu W,Xue BJ,Ya WW,Jing XW, En QY, Zheng CW et al.High dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia .Blood. 2016;127:296-302.